BridgeMD
New treatment option for Chronic Obstructive Pulmonary Disease (COPD)
Official title A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
ClinicalTrials.gov ID: NCT07382258
What this study is testing
- What it's testing
- This clinical trial aims to assess the impact on exercise tolerance and the safety of inhaled nitric oxide in subjects with moderate-to-severe COPD. The findings are expected to contribute to the development of safe and effective therapeutic strategies for COPD management.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 75
You may be able to join if
- Aged between 40 and 75 years, inclusive.
- History of smoking with a cumulative exposure of ≥10 pack-years, and having ceased smoking for at least one month prior to study participation.
- Diagnosis of moderate-to-severe COPD confirmed by post-bronchodilator spirometry: FEV1/FVC \< 0.7 and FEV1 between 30% and 80% of predicted value.
- Willing and able to provide written informed consent and comply with all study-related procedures.
You likely can't join if
- Pregnancy or lactation.
- Use of nicotine-containing products (e.g., patches, gum) within the past month.
- Current diagnosis of asthma or any other active respiratory condition considered non-COPD by the investigator.
- Physical obstruction of the nasal passages.
- Experienced a COPD exacerbation within the past month requiring initiation or escalation of systemic corticosteroids.
- Impaired left ventricular systolic function, defined as left ventricular ejection fraction (LVEF) \< 50%.
See the full eligibility criteria
- Aged between 40 and 75 years, inclusive.
- History of smoking with a cumulative exposure of ≥10 pack-years, and having ceased smoking for at least one month prior to study participation.
- Diagnosis of moderate-to-severe COPD confirmed by post-bronchodilator spirometry: FEV1/FVC \< 0.7 and FEV1 between 30% and 80% of predicted value.
- Willing and able to provide written informed consent and comply with all study-related procedures.
- Pregnancy or lactation.
- Use of nicotine-containing products (e.g., patches, gum) within the past month.
- Current diagnosis of asthma or any other active respiratory condition considered non-COPD by the investigator.
- Physical obstruction of the nasal passages.
- Experienced a COPD exacerbation within the past month requiring initiation or escalation of systemic corticosteroids.
- Impaired left ventricular systolic function, defined as left ventricular ejection fraction (LVEF) \< 50%.
- Significant valvular heart disease (moderate/severe aortic or mitral stenosis/regurgitation) or prior mitral valve replacement.
- Use of approved pulmonary hypertension medications (e.g., sildenafil, bosentan, prostacyclins) within 30 days prior to screening or during the study.
- Participation in another treatment clinical trial involving drugs or devices within 30 days prior to enrollment.
- Any other medical or psychiatric condition that, in the investigator's judgment, would compromise patient safety or study integrity.
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.